Evidence to Practice
@evi2prac
Followers
105
Following
98
Media
135
Statuses
205
We bring new evidence from clinical trials to the clinical community via educational activities, enabling informed uptake of new treatments and best practice.
Melbourne, Victoria
Joined September 2018
Congratulations to our member @WannJiaLoh for hosting a Lp(a) #Awareness Day in conjunction with Changi General Hospital (CGH). Her goal was to 'unpack the who, what, why and how's of #lipoprotein(a).' Find out more information about Dr Wann’s initiative https://t.co/hQGpRdrWLk
0
2
6
This Thursday, 16th March at 8.00pm AEDT via @apsc_office @ProfSNicholls will summarise the results from the CLEAR Outcomes trial. Join Steve and our panel as we discuss this important trial and the new option it presents for patients with statin intolerance.
1
3
6
Join us at our annual Symposium to discuss the latest topical and developing areas in cardiology! Tickets are going fast so register today.
0
0
0
Our Webinar will be held on Tuesday, 20th September from 7.00pm - 8.30pm and is free to attend.
0
0
2
If you're after a breakdown of the major Clinical Trials presented at ESC 2022 - we've got you covered! Register for tickets and join our expert faculty as we discuss the major implications of these results for practice in Australia. https://t.co/SeDARTTTec
eventbrite.com.au
E2P Clinical Trial Forum
2
0
2
Further investigation needed into the potential for Asundexian as a safer anticoagulant in an adequately powered phase 3 clinical trial
0
0
2
On top of DAPT there was no increase in significant (BARC 2,3 or 5) or any bleeding with any dose of Asundexian compared with placebo
1
0
1
PACIFIC-AMI demonstrating that Asundexian 50mg daily on top of DAPT resulted in near complete (>90%) inhibition of factor Xla inhibition following acute MI #ESCCongress
1
1
2
The INVICTUS study showing that in RHD-AF, compared to rivaroxaban,VKAs have a lower mortality and reduced ischemic stroke without increasing the risk of major bleeding. VKAs should remain the standard of care in RHD-AF
0
2
5
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress
https://t.co/0umSDn5HkO
1
70
193
ALL-HEART - Allopurinol added to usual care did not improve outcomes in patients aged over 60 years with IHD (but no gout) #ESCCongress
0
0
2
Nor did PCI incrementally improve left ventricular ejection fraction or provide a sustained difference in quality of life
0
0
0
PCI did not reduce the composite incidence of all-cause mortality or hospitalisation for heart failure at a median of 3.4 years.
1
0
0
The REVIVED study (Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction) demonstrating that patients with ischaemic cardiomyopathy continue to have high rates of mortality and hospitalisation for HF even with contemporary medical and device therapy.
2
1
3
This study as well as other recent RCTs and observational data point to the potential for influenza vaccination to be standard practice at discharge for CVD.
0
0
0
The role of high dose flu vaccine in CVD is unresolved however likely the best choice for those 65 years +
0
0
0
The DANFLU-1 trial (High-dose vs. standard-dose quadrivalent influenza vaccine in elderly adults) demonstrates that the incidence of hospitalisation for influenza or pneumonia was significantly lower in the QIV-HD group compared to the QIV-SD group.
2
0
1
The results of ADVOR highlight the importance of targeting congestion both early and aggressively and support the use of natriuresis as an indicator or diuretic response.
0
0
0
ADVOR (Acetazolamide in Acute Decompensated Heart Failure with Volume OveRload) demonstrating that the addition of 500mg IV acetazolamide to standardised IV loop diuretic was associated with a 46% higher incidence of successful decongestion after 3 days. #ESCCongress
2
1
5
Subgroup analyses indicate that the younger age group (65-69 years) may benefit from screening
0
0
0